Drugs that lack single-agent activity: are they worth pursuing in combination?

被引：26

作者：

Gyawali, Bishal ^{[1
]}

Prasad, Vinay ^{[2
,3
,4
]}

机构：

[1] Nobel Hosp, Dept Haematooncol, Kathmandu 21034, Nepal

[2] OSHU, Div Hematol Oncol, Knight Canc Inst, Portland, OR 97239 USA

[3] OSHU, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA

[4] Ctr Eth Hlth Care, 3181 South West Sam Jackson Pk Rd, Portland, OR 97239 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2017年 / 14卷 / 04期

关键词：

METASTATIC BREAST-CANCER; MULTIPLE-MYELOMA; TRIAL; MULTICENTER; DOXORUBICIN; BORTEZOMIB;

D O I：

10.1038/nrclinonc.2017.27

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Over the past decade, many anticancer drugs have been approved for use only in combination regimens and only in palliative settings, despite having negligible single-agent activity in the same disease. We examine whether these agents provide any tangible clinical benefits and are worthy of continued development, or whether R&D efforts would be better focused elsewhere.

引用

页码：1 / 2

页数：2

共 9 条

[1] Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens [J].

Blackwell, K. L. ;

Pegram, M. D. ;

Tan-Chiu, E. ;

Schwartzberg, L. S. ;

Arbushites, M. C. ;

Maltzman, J. D. ;

Forster, J. K. ;

Rubin, S. D. ;

Stein, S. H. ;

Burstein, H. J. .

ANNALS OF ONCOLOGY, 2009, 20 (06) :1026-1031

[2] Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study [J].

Dimopoulos, Meletios ;

Siegel, David S. ;

Lonial, Sagar ;

Qi, Junyuan ;

Hajek, Roman ;

Facon, Thierry ;

Rosinol, Laura ;

Williams, Catherine ;

Blacklock, Hilary ;

Goldschmidt, Hartmut ;

Hungria, Vania ;

Spencer, Andrew ;

Palumbo, Antonio ;

Graef, Thorsten ;

Eid, Joseph E. ;

Houp, Jennifer ;

Sun, Linda ;

Vuocolo, Scott ;

Anderson, Kenneth C. .

LANCET ONCOLOGY, 2013, 14 (11) :1129-1140

[3] Same Data; Different Interpretations [J].

Gyawali, Bishal ;

Prasad, Vinay .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (31) :3729-+

[4]

Inman S., 2014, ONCLIVE

[5] Addition of Bevacizumab to Chemotherapy for Treatment of Solid Tumors: Similar Results but Different Conclusions [J].

Ocana, Alberto ;

Amir, Eitan ;

Vera, Francisco ;

Eisenhauer, Elizabeth A. ;

Tannock, Ian F. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (03) :254-256

[6] Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma [J].

Orlowski, Robert Z. ;

Nagler, Arnon ;

Sonneveld, Pieter ;

Blade, Joan ;

Hajek, Roman ;

Spencer, Andrew ;

Robak, Tadeusz ;

Dmoszynska, Anna ;

Horvath, Noemi ;

Spicka, Ivan ;

Sutherland, Heather J. ;

Suvorov, Alexander N. ;

Xiu, Liang ;

Cakana, Andrew ;

Parekh, Trilok ;

San-Miguel, Jesus F. .

CANCER, 2016, 122 (13) :2050-2056

[7] Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193) [J].

Sledge, GW ;

Neuberg, D ;

Bernardo, P ;

Ingle, JN ;

Martino, S ;

Rowinsky, EK ;

Wood, WC .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (04) :588-592

[8] Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma [J].

Wolf, Jeffrey L. ;

Siegel, David ;

Goldschmidt, Hartmut ;

Hazell, Katharine ;

Bourquelot, Priscille M. ;

Bengoudifa, Bourras R. ;

Matous, Jeffrey ;

Vij, Ravi ;

de Magalhaes-Silverman, Margarida ;

Abonour, Rafat ;

Anderson, Kenneth C. ;

Lonial, Sagar .

LEUKEMIA & LYMPHOMA, 2012, 53 (09) :1820-1823

[9] A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma [J].

Zonder, Jeffrey A. ;

Mohrbacher, Ann F. ;

Singhal, Seema ;

van Rhee, Frits ;

Bensinger, William I. ;

Ding, Han ;

Fry, John ;

Afar, Daniel E. H. ;

Singhal, Anil K. .

BLOOD, 2012, 120 (03) :552-559

← 1 →